Early breast cancer¹

KISQALI®, in combination with aromatase inhibitors, is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, stage II and III early breast cancer at high risk of recurrence.

Metastatic breast cancer¹

KISQALI® is indicated for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor or fulvestrant, as initial endocrine-based therapy or following prior endocrine therapy.

HER2-, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive